SEC Form 4 · accession 0001179110-17-006331
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert James Wills
Director
Period of report
Apr 27, 2017
Accepted (ET)
May 1, 2017 · 7:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.48 | Apr 27, 2017 | A | 27,000 | A | — | Apr 26, 2027 | Common Stock | 27,000 | 27,000 | D |
Explanation of responses
- F1The option vests in equal monthly installments over the eight-month period beginning on the vesting commencement date of April 15, 2017, subject to the Reporting Person's continuous service to the Issuer; provided, however, that this option will stop vesting on the date the Reporting Person resigns as the Executive Chairman of the Issuer, but continue to serve as the director of the Issuer.